Aphria (TSX:APH)–alongside its partners in the US cannabis space Liberty Health Sciences (CSE:LHS)–released a response on Monday (August 21) regarding the clarification by the TMX Group on regulatory engagement for cannabis companies listed in Canada but with business activities in the US.
The statement from the TMX indicated it had engaged with the Canadian Securities Exchange to clear the securities of issuers with businesses in the US. The group said it will provide an update at a later date once it had cleared up the entire situation.
“We are working with regulators to arrive at a solution that will clarify this matter for issuers, investors, participants and the public,” the TMX said. They did, however, clarify there was no CDS (Canadian Depository for Securities) ban for cannabis stocks with business in the US.
This is due to Canadian cannabis companies listed on the TSX with potential or legitimate business opportunities in the States currently existing in a gray space when it comes to the legal terms of cannabis. In the US cannabis is illegal on a federal level, however, several states have legalized the drug and opened up business models for companies to sell either medically or in some cases even recreationally as well.

The role of CDS and the danger of a potential ban

As reported by the Globe and Mail, in the article that featured an interview with Lou Eccleston, CEO at TMX Group, in which the potential of a CDS ban was proposed, the value of CDS ensure that trades in the market end up in the right spot.
“If CDS refuses to clear and settle trades in these cannabis stocks, it would make those companies unattractive to many investors, hindering parts of the budding marijuana industry,” the report indicated.
Vic Neufeld, president, and CEO of Aphria said he was pleased both with the confirmation of no CDS ban and the pursuit by the TMX to clear this situation further. Neufeld added they will continue their dialogue with the TSX and CDS for this.
“Aphria’s common shares have traded on the TSX and previously the TSX Venture Exchange for almost 3 years during which time we have raised over $216 million from investors by way of five offerings by short form prospectus, all of which have been settled by CDS, and we look forward to this continued support from the TMX Group,” Neufeld said in a statement.
Aphria doesn’t plan to slow down their US business. According to the company, both Aphria and Liberty are focused on their existing strategies related to the medical cannabis market in the two countries.
George Scorsis, CEO of Liberty said they are prepared to work alongside the TMX in order to clarify the situation for the two companies and “all Canadian capital market participants.”

Investor Takeaway

Aphria has held business interests in the US, admittedly, since 2015. When it comes to the cannabis industry in the US, despite the illegal nature of it on a federal level, the potential seems too great to be left behind.
On Monday shares of  Aphria saw a 1.88 percent decrease on the TSX. By market closure, the company’s stock traded at $5.73.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less